If not administered properly, health experts say medications like Ozempic, Mounjaro, and Wegovy can cause gastrointestinal ...

People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...

A network meta-analysis reveals age-dependent variations in efficacy of popular diabetes drugs, with SGLT2 inhibitors showing ...

After pre-announcing that its full-year revenue would come in below its original guidance, Eli Lilly (NYSE: LLY) announced ...

SGLT-2 inhibitors and GLP-1 receptor agonists are linked to a reduced risk of COPD exacerbations in patients with type 2 ...

The global Diabetes Drugs Market size was valued at USD 84.65 billion in 2024 and is expected to be worth around USD 177.74 ...

Age differences are seen in the efficacy of treatments for type 2 diabetes, according to a study published online Feb ...

Groundbreaking research reveals how common diabetes medications might offer unprecedented protection against heart attacks ...

UK: A recent consensus statement from leading UK medical organizations-including the Association of Anaesthetists,the ...

Though highly effective, medications for the prevention of chronic kidney disease progression are under-utilized, emphasizing the need for better use of prognostic tools.

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

Certain diabetes medications may have additional health benefits for older adults, scientists from the University of Glasgow ...